TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Success rate of periapical evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of CBCT evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity on the Beck Depression Inventory-II (BDI-II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission on the PHQ-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Zinc intake in men
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vitamin B(12) intake in combined gender groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Emergence agitation measured by the Richmond Agitation Sedation Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Emergence agitation measured by the Riker Sedation‐Agitation Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bacterial composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Global Assessment of Functioning (GAF) Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: venographically-documented upper extremity thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of fatal myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Use of analgesics
Endpoint domain: Adverse events/effects
Primary endpoint: Serum 25‐(OH)D levels greater than 50 nmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterograde amnesia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of CHF
Endpoint domain: Mortality/survival
Primary endpoint: Mortality rate after CHF hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: severe neutropenia or death
Endpoint domain: Mortality/survival
Primary endpoint: Nocturnal systolic blood pressure decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nocturnal diastolic blood pressure decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase of active range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Grasping performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Temporal and spatiotemporal control of reaching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative satisfaction with anesthesia care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: serum free IgE concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: nasal response to allergen challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FPE (First Pass Effect)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower rate of hemorrhagic transformation
Endpoint domain: Adverse events/effects
Primary endpoint: Motion artifact score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal timing of arterial phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage correct on Sock Sorting task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on Sidewalk Tracking task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on Walking Direction Discrimination task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appearance of exogenous phenylalanine in the circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary protein-derived phenylalanine availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood ammonia concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: plasma leucine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary leucine excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper gastrointestinal symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Mean UCVA improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of progression to AIDS or death
Endpoint domain: Mortality/survival
Primary endpoint: Development of non-AIDS-defining opportunistic infections
Endpoint domain: Adverse events/effects
Primary endpoint: Mean changes in CD4 lymphocyte numbers/mm3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Death or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Severe liver-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of cases with HPV 16/18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion containing HPV16/18 plus non-vaccine HPV types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: course of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of IOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean IOC time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of use graded by surgeons
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median AAUCMB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median CD4+ T‐cell increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Prolongation of latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of treatment acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-h ambulatory SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postprocedural hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Overall success rate with unmodified empiric therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of new infections
Endpoint domain: Adverse events/effects
Primary endpoint: Time from contamination to final culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopist satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 6-sulpho LacNAc + dendritic cell (slanDC) frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in postprandial glycemic excursions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum glycated albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin levels at 30 and 120 minutes after a meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of major and clinically relevant non‐major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Mean WDT peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-syncopal or syncopal symptoms during tilt tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gingival Crevicular Fluid (GCF) Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach clinically significant plasma concentration of cortisol (>200 nmol/l)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean peak plasma cortisol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of evidence-based guideline practices followed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blast cell reduction in the bone marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median duration until neutrophil recovery >500/μl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: duration of thrombocytopenia (time to >20000/μl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: NBD scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risankizumab clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal-phase elimination half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minimal skin irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: acceptable wearability of the wearable sensor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: usability feedback from patients with SMI and caregivers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective well-being improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in symptomology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gains in general life functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Minnesota Living Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Temperature at the end of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tenofovir concentrations in hair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FI severity score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability at 1 year
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Back+leg pain at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of ExT for detection of significant coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: UL motor function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choice of fruit over energy-dense snacks
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: ASAS20 response at week 58
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of infliximab infusions administered after week 10
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Disease remission (28-joint Disease Activity Score <2.6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIPS scores indicating relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net fat-free mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of plasma lipid and apolipoprotein profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Attenuation of biomarkers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increased insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of installed and functioning tippy taps for hand washing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean temperature change after 4 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications related to ablation
Endpoint domain: Adverse events/effects
Primary endpoint: Humor
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diabetes-related complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of care regarding antidiabetic medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall symptom improvement (BPRS total score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in LPA (Light Physical Activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meeting 60 minutes per day guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular ejective factor (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TIMI blood flow grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in serum 25OHD concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived appraisal support
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: received tangible support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: number of physical activity supporters
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: ACR 20 criteria response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR 50 criteria response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P1 latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in mammographic density (MPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of medical records with evidence of screening and intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lifetime risk of major depression
Endpoint domain: Mortality/survival
Primary endpoint: Patient preference for diagnostic examinations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Smoke-free home reporting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time of awareness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of nausea, vomiting, and chill
Endpoint domain: Adverse events/effects
Primary endpoint: QAOT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Vitamin D values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FSS scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HFRDIS scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knowledge/awareness of CRC screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-provider communication
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Final best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interocular disparity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in metamorphopsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete clearance of skin condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibroid related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amenorrhoea induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nadir epiglottic pressure during respiratory events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in psychological resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Definite staphylococcal sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: exhaled H(2)O(2) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3D resultant moments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak frontal‐plane moments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per additional kilogram lost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost per blood pressure reduction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: epoetin dosage requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma HIV RNA load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delay in the appearance of the first AIDS-defining event
Endpoint domain: Mortality/survival
Primary endpoint: reduction in the cumulative incidence of AIDS-defining events
Endpoint domain: Mortality/survival
Primary endpoint: neurocognitive improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate defined as 5 mm Hg<final IOP≤15 mm Hg without further surgical intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Decrease in the number of medications
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Propulsive vertical ground reaction force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pneumococcal IgG concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Forced expiratory volume in 1‐second/forced vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced expiratory flow between 25% and 75% of the FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tumor Necrosis Factor‐alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Creatinine kinase‐MB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentrations of high-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Low-density lipoprotein/high-density lipoprotein ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Depressive symptom severity profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QT interval changes (ΔΔQTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gingival Interproximal Index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: habit withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lifetime costs
Endpoint domain: Resource use
Primary endpoint: HRSD core symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRSD total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPI total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of C. difficile spores on skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Endoscopic findings normal in distal esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Visick I grading
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: leptin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: preservation of post-RP erectile function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: uptake of malaria diagnostic testing at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AUC(0-24) of atorvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AUC(0-24) of pitavastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day 15 morning trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FENO at day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Carbon monoxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Puffs per session
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma zinc curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes